Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Multiple Myeloma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Chromosome 17 deletion 1Blast Crisis 1Amyloidosis 1

Interventions

Imatinib Mesylate 10Cyclophosphamide 9fludarabine 8nilotinib 7fludarabine phosphate 7Dasatinib 6Busulfan 6Whole-Body Irradiation 5Tacrolimus 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Melphalan 5Cytarabine 5Stem Cell Transplantation 4Filgrastim 4Alemtuzumab 4Cyclosporine 3Bone Marrow Transplantation 3Antilymphocyte Serum 3thymoglobulin 2ruxolitinib 2ponatinib 2plerixafor 2bosutinib 2Thiotepa 2Sirolimus 2Granulocyte Colony-Stimulating Factor 2Everolimus 2venetoclax 1vatalanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × auricularum × Clear all
NCT03576547 2025-05-08

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Terminated
9 enrolled 11 charts
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡